OnKure Therapeutics (NASDAQ:OKUR) Issues Quarterly Earnings Results

OnKure Therapeutics (NASDAQ:OKUR) posted its quarterly earnings results on Tuesday. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.37), FiscalAI reports.

OnKure Therapeutics Stock Down 1.7%

Shares of OKUR stock traded down $0.08 during mid-day trading on Tuesday, hitting $4.52. 95,002 shares of the stock were exchanged, compared to its average volume of 142,280. The firm has a fifty day moving average of $4.04 and a 200 day moving average of $3.30. OnKure Therapeutics has a 52-week low of $1.70 and a 52-week high of $5.38. The company has a market cap of $61.79 million, a PE ratio of -1.02 and a beta of 0.36.

Wall Street Analysts Forecast Growth

Several research firms have commented on OKUR. Wall Street Zen raised shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Weiss Ratings raised shares of OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Finally, HC Wainwright lowered their price target on shares of OnKure Therapeutics from $34.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, March 16th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, OnKure Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $27.00.

Institutional Investors Weigh In On OnKure Therapeutics

Hedge funds have recently modified their holdings of the company. XTX Topco Ltd purchased a new stake in shares of OnKure Therapeutics during the 2nd quarter worth about $25,000. Jane Street Group LLC purchased a new stake in shares of OnKure Therapeutics during the 4th quarter worth about $56,000. Hsbc Holdings PLC acquired a new position in shares of OnKure Therapeutics during the 4th quarter worth about $58,000. Barclays PLC raised its position in shares of OnKure Therapeutics by 4,286.8% during the 4th quarter. Barclays PLC now owns 27,242 shares of the company’s stock worth $79,000 after purchasing an additional 26,621 shares during the last quarter. Finally, Rangeley Capital LLC acquired a new position in shares of OnKure Therapeutics during the 2nd quarter worth about $71,000. 90.98% of the stock is owned by hedge funds and other institutional investors.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.